Browse by Medical Category
Center for the Study of IBD
The overarching goal of the CSIBD Clinical Core is to provide an infrastructure that facilitates the translation of basic research findings into the clinic. The core is led by Ramnik Xavier, MD, PhD (director), Andrew Chan, MD, MPH (co-director), and Ashwin Ananthakrishnan, MD, MPH (technical director). All three of these individuals are gastroenterologists with particular expertise and interest in translational medicine relating to IBD. The key component of this core is the PRISM registry (Prospective Registry in IBD Study at MGH), which includes more than 2,000 enrolled patients with IBD as well as healthy controls.
The Clinical Core maintains an active database encompassing patients with IBD seen at MGH. Because the entire GI staff at MGH participate in a common group practice organization and all are committed to the success of this project, it has been possible to capture nearly all relevant patients for this base. Retrospective review of hospital admissions suggests that < 5% of patients with an identified diagnosis of IBD are cared for without the participation of members of the GI group. Furthermore, as most of the small numbers missed by these criteria are admitted for surgical procedures, this group is identified through the activity of the tissue collection mechanisms of this core. Demographic data are available on all patients seen through the GI group and hospital at large. The database includes demographics and salient disease features, including symptoms, duration, medications, location of disease (means of documentation), extraintestinal manifestations, endoscopy, surgery, pathology, family history and hospitalizations. Patients are also asked to indicate if they would be willing to participate in CSIBD-related research activities through the PRISM cohort. CSIBD investigators with IRB-approved projects have access to this database to identify patients needed for study. An additional responsibility of this core is the recruitment of patients for specific study needs through notification of all MGH GI Unit practitioners.
Recently expanded services include expansion of the patient registry, refined biospecimen collection algorithms, development of standard operating procedures (SOP) for processing of tissues, facilitation of regulatory paperwork and institutional review board (IRB) approval of protocols, integration of genetic and microbiome data with clinical data, expansion of depth of phenotyping and assessment of exposures, and streamlined user access to clinical and biospecimen data.
Back to Top